Synthetic Human Secretin in Children With Autism

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00036244

Enrollment

Unknown

Registered

2002-05-09

Start date

2002-04-30

Completion date

2004-01-31

Last updated

2005-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism

Brief summary

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Interventions

DRUGRG1068 (Synthetic Human Secretin)

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

32 Months to 59 Months

Healthy volunteers

Inclusion criteria

Autism

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026